2Morrow, Inc., a leader in offering evidence-based, digital health platforms, announces a $1.5M investment led by Seattle area life science investor WRF Capital. The funding will be used to support growth of 2Morrow’s current platform and expansion into medical grade, digital therapeutic solutions for chronic conditions.
Human behaviors drive over half of today’s healthcare costs, and the mental and emotional toll of living with a chronic condition can result in increased instances of depression, anxiety and substance use disorders. The CDC recommends including behavioral modification or therapy in most care plans, however, these treatments are seldom offered due to lack of training, access, stigma or cost. Digitally addressing health through behavioral science, 2Morrow’s expanded platform will make it easier for healthcare providers to prescribe and distribute behavioral programs alongside other treatment options.
“We look forward to partnering with the 2Morrow team as it builds on its experience in the behavior modification arena to make high quality, evidence-based digital therapeutics available,” says Loretta Little, Managing Director, WRF Capital. “Physicians and patients need user-friendly, effective digital solutions that complement currently prescribed treatments.”